Evidence map›Paper›PMID 34783986›Full record

ArticleGenes & genomics2022

Novel blood-based hypomethylation of SH3BP5 is associated with very early-stage lung adenocarcinoma.

Rong Qiao, Runbo Zhong, Chunlan Liu, Feifei Di, Zheng Zhang, Ling Wang, Tian Xu, Yue Wang, Liping Dai, Wanjian Gu and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Genes & genomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. The association between blood-basedLung cancer management · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. [Peripheral bloodNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Rong Qiao *Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, 200030, China.
Runbo Zhong *Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, 200030, China.
Chunlan LiuDepartment of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, 210000, China.
Feifei DiNanjing TANTICA Biotechnology Co. Ltd, Nanjing, 210000, China.
Zheng ZhangNanjing TANTICA Biotechnology Co. Ltd, Nanjing, 210000, China.
Ling WangNanjing TANTICA Biotechnology Co. Ltd, Nanjing, 210000, China.
Tian XuDepartment of Clinical Laboratory, Jiangsu Province Hospital of Chinese Medicine, Nanjing, 210000, China.
Yue WangShanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, 200030, China.
Liping DaiHenan Institute of Medical and Pharmaceutical Sciences, Academy of Medical Science, Zhengzhou University, Zhengzhou, 450052, China.
Wanjian GuDepartment of Clinical Laboratory, Jiangsu Province Hospital of Chinese Medicine, Nanjing, 210000, China.
Baohui HanShanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, 200030, China. 18930858216@163.com.
Rongxi YangDepartment of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, 210000, China. rongxiyang@njmu.edu.cn.ORCID 0000-0002-6655-1986
Shanghai Chest Hospital · CNJiangsu Province Hospital · CNNanjing Medical University · CNNanjing University of Chinese Medicine · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEarly detection is essential to improve the survival of lung cancer (LC). The quantitative measurement of specific DNA methylation changes in the peripheral blood could provide an efficient strategy for the detection of early cancer.

objectiveWe applied a candidate approach and assess the association between blood-based SH3BP5 methylation and the risk of lung adenocarcinoma (LUAD) in a case-control cohort.

methodsThe methylation level of four CpG sites in the promoter of SH3BP5 gene was quantitatively determined by mass spectrometry in 171 very early-stage LUAD patients (93.6% LUAD at stage I) and 190 age and gender-matched controls. The logistic regression and non-parametric tests were used for the statistical analyses.

resultsWe observed a significant association between decreased methylation of SH3BP5_CpG_4 in the peripheral blood and increased risk of LUAD (odds ratio (OR) per-10% methylation = 1.51, P = 0.006, FDR = 0.024), and even for the LUAD at stage I (OR per-10% methylation = 1.53, P = 0.006, FDR = 0.024). Moreover, the lower quartile of SH3BP5_CpG_4 methylation was correlated with increased risk for LUAD with a P trend of 0.011. Further investigation disclosed that the hypomethylation of SH3BP5_CpG_4 was mostly associated with LUAD in younger subjects (OR per-10% methylation = 2.02, P = 0.010, age < 55 years old) and probably could be enhanced by advance stage.

conclusionOur study revealed an association between blood-based SH3BP5 hypomethylation and very early-stage LUAD, which provides a novel support for the blood-based methylation signatures as a potential marker for the evaluation of cancer risk.

Indexed as

Adaptor Proteins, Signal TransducingAdenocarcinoma of LungDNA MethylationLung NeoplasmsCase-Control StudiesHumansMiddle AgedPromoter Regions, GeneticAdaptor Proteins, Signal TransducingSH3BP5 protein, humanBiomarkerDNA methylationEarly stageLung cancerSH3BP5

Identifiers

PMID34783986
OpenAlexW3211895246

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.